Very disappointing call. IMO both Kelly and Pourh

Very disappointing call. IMO both Kelly and Pourhassan at times were not professional in their responses, especially when the compensation and stock discussion occurred. NP has done a great job getting this molecule to demonstrate efficacy; however, is not able to get it over the finish line with at least one approval. It may be time for all shareholders to think critically about a new leadership team. The FDA will continue to stone wall us at the behest of Gilead. I will be voting NO across the board.